RBC Capital Maintains Sector Perform on BioMarin Pharmaceutical, Lowers Price Target to $62

Benzinga Newsdesk www.benzinga.com Negative 90.5%

Neg 90.5% Neu 0% Pos 0%

RBC Capital analyst Luca Issi maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and lowers the price target from $66 to $62.